Skye Bioscience Inc
NASDAQ:SKYE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Banimmo SA
LSE:0NG8
|
BE |
|
Kenvue Inc
NYSE:KVUE
|
US |
|
Adani Ports and Special Economic Zone Ltd
NSE:ADANIPORTS
|
IN |
|
Himatsingka Seide Ltd
NSE:HIMATSEIDE
|
IN |
Skye Bioscience Inc
Total Assets
Skye Bioscience Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Skye Bioscience Inc
NASDAQ:SKYE
|
Total Assets
$28.3m
|
CAGR 3-Years
46%
|
CAGR 5-Years
60%
|
CAGR 10-Years
23%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Assets
$134B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Assets
$59B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Assets
$90.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Assets
$25.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Assets
$40.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
Skye Bioscience Inc
Glance View
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The Company’s products programs include THCVHS and CBDVHS. The firm's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). The company chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.
See Also
What is Skye Bioscience Inc's Total Assets?
Total Assets
28.3m
USD
Based on the financial report for Dec 31, 2025, Skye Bioscience Inc's Total Assets amounts to 28.3m USD.
What is Skye Bioscience Inc's Total Assets growth rate?
Total Assets CAGR 10Y
23%
Over the last year, the Total Assets growth was -61%. The average annual Total Assets growth rates for Skye Bioscience Inc have been 46% over the past three years , 60% over the past five years , and 23% over the past ten years .
